Published in the October 26 issue of The Lancet, the study is the result of a five-year collaboration between a Yale and South African team of researchers who aim to integrate HIV and TB care and treatment.
TB is the most common cause of death and illness in those with HIV infection in sub-Saharan Africa. HIV greatly increases the risk of active TB disease and about 80 percent of patients with active TB in the province of KwaZulu Natal, South Africa, are co-infected with HIV. Death rates of up to 40 percent per year have been reported in patients with both HIV and TB.
Led by senior author Gerald Friedland, M.D., director of the AIDS Program at Yale and Professor in the Departments of Medicine and Epidemiology and Public Health, the study measured the prevalence of multi-drug resistant (MDR) tuberculosis and extensively drug-resistant (XDR) tuberculosis in a hospital in KwaZulu Natal. Between January 2005 and March 2006, sputum samples from 1,539 patients were screened. MDR TB was found in 221 patients and of those, 53 had XDR TB. Those patients with XDR who were tested for HIV were found to be co-infected. All but one of the 53 patients with both XDR TB and HIV died, with an average survival of 16 days.
"This is an issue of grave worldwide importance," said Friedland. "MDR and XDR carry the danger of blunting or reversing the success of TB programs and the roll-out of anti-retroviral therapies for HIV where they are desperately needed in resource limited settings. Urgent intervention is necessary, especially now that we know that MDR tuberculosis is far more prevalent than previously thought and that XDR tuberculosis has been transmitted to HIV co-infected patients and associated with high mortality."
Future studies will involve defining the extent and conseq uences of the problem in greater detail, Friedland said, with operational research focused on quickly determining what kind of infection control practices can practically and feasibly be instituted to reduce the transmission of this lethal form of tuberculosis to others.
Friedland said there is a desperate need for new diagnostic tests and treatment for TB. "It is still being diagnosed the same way it was in 1882," he said. "Modern technology for diagnosis and new treatment needs to be developed urgently. The last approved TB drug was 40 years ago."
Related biology news :
1. New therapy for HIV/AIDS eliminates needles and excessive toxicity
2. South Africa still debating how to tackle HIV/AIDS when 5 million are infected
3. AIDS expert says global strategy needed to combat feminization of HIV/AIDS
4. Progress on HIV/AIDS significant but insufficient
5. HIV/AIDS rates in Tijuana, Mexico increasing at alarming rate
6. International HIV/AIDS trial finds continuous antiretroviral therapy superior to episodic therapy
7. Study defines effective microbicide design for HIV/AIDS prevention
8. Rhesus monkeys in Nepal may provide new alternative for HIV/AIDS research
9. Cornell researcher helping develop quick, cheap HIV/AIDS test
10. Newly discovered virus linked to childhood lung disorders and Kawasaki disease
11. Low level of extinction during ice age linked to adaptability